0000950170-23-048632.txt : 20230918 0000950170-23-048632.hdr.sgml : 20230918 20230918184826 ACCESSION NUMBER: 0000950170-23-048632 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230918 DATE AS OF CHANGE: 20230918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheng Andrew CENTRAL INDEX KEY: 0001778307 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 231262141 MAIL ADDRESS: STREET 1: 170 HARBOR WAY, 3RD FLOOR STREET 2: C/O AKERO THERAPEUTICS, INC. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2023-09-01 0001744659 Akero Therapeutics, Inc. AKRO 0001778307 Cheng Andrew C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 true true false false President and CEO true Common Stock 2023-09-01 4 M false 25000 6.36 A 487680 D Common Stock 2023-09-01 4 S false 24873 49.7675 D 462807 D Common Stock 2023-09-01 4 S false 127 50.2400 D 462680 D Stock Option (Right to Buy) 6.36 2023-09-01 4 M false 25000 0.00 D 2029-01-15 Common Stock 25000 65000 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. The options are vested and currently exercisable. /s/ Jonathan Young, Attorney-in-Fact 2023-09-18